The death toll from the Ebola outbreak in the Democratic Republic of Congo has surpassed 3,000, with more than 6,100 confirmed cases since the epidemic was declared in mid-May. The outbreak began in the northeastern Ituri province and spread to six provinces, while also briefly crossing into neighboring Uganda before that country declared its own outbreak over. With a fatality rate of roughly 49 percent, young children are experiencing especially high mortality. This marks the country’s seventeenth recorded Ebola outbreak, and it is complicated by involving the Bundibugyo strain, for which there is no specific approved vaccine or treatment.
Despite the lack of an approved vaccine for this strain, health authorities and international partners are distributing tens of thousands of doses of the Ervebo vaccine to test its effectiveness against Bundibugyo and to protect frontline healthcare workers. Clinical trials for two experimental antiviral treatments also began earlier in the year. The virus spreads via direct contact with bodily fluids, causing severe fever, vomiting, diarrhea, and often fatal internal bleeding.
Containment efforts are being complicated by weak health infrastructure and difficult terrain in the affected provinces. While the outbreak’s scale has drawn growing international attention and funding, global focus remains heavily concentrated on the war in the Middle East.